Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400952 | 0.82 | KMT2A (0.62) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL515055 | 0.80 | KMT2A (0.50) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL6524000 | 0.78 | KMT2A (0.48) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL9421747 | 0.78 | FAAH (0.60) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL394806 | 0.78 | KMT2A (0.53) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL3229364 | 0.78 | CA1 (0.60) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL515054 | 0.78 | KMT2A (0.48) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL1149296 | 0.78 | KMT2A (0.48) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL10289671 | 0.78 | KMT2A (0.58) | KMT2ACA1CA2CA9IDO1 | |
| SCHEMBL9200717 | 0.77 | PLCG1 (0.46) | CA1CA2CA9IDO1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619095-B2 | Process for the preparation of indolone derivative | ALEMBIC LIMITED (IN) | 2009-11-17 | — | — | US | claimed |
| EP-1848691-B1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LTD (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | ALEMBIC LIMITED (IN) | 2008-10-23 | — | — | US | claimed |
| EP-1848691-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | Alembic Limited (IN) | 2007-10-31 | — | — | EP | claimed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | claimed |
| EP-0255134-B1 | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | claimed |
| EP-4400492-A1 | ACRIDINE COMPOUND | OSAKA UNIVERSITY (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| CN-118103359-A | Preparation method of eribulin derivative | 江苏恒瑞医药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| CN-117940408-A | Acridine compounds | 国立大学法人大阪大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20240132518-A1 | CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PREPARATION METHOD THEREFOR | SHANGHAI SENHUI MEDICINE CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| EP-0115334-A1 | Benzo-heterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-08 | — | — | EP | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132518-A1 | CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PREPARATION METHOD THEREFOR | WASF2, MRPL21, CLSPN | KMT2A 4363/4885CA1 4730/4885CA2 4379/4885 |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | HTR3C, HTR3B, HTR1B | KMT2A 1799/4885CA1 4526/4885CA2 3810/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | KMT2A 1736/4885CA1 4851/4885CA2 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.